Phi et al. [24] reported that mammography’s specific ability to detect microcalcifications is especially valuable in BRCA2 mutation carriers because the proportion of calcified DCIS in women who are BRCA2 mutation carriers was larger than that of women who are BRCA1 mutation carriers. This evidence concerns the gene BRCA2 and ductal breast carcinoma in situ.